Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Congenital Syphilis Treatment Trial (CONSISTENT): Phase IV, Open-label, Randomized Controlled Trial of Amoxicillin vs Benzathine Penicillin in Neonates with Possible Congenital Syphilis

Award Number: U01AI195199
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/12/2026
PERIOD OF PERFORMANCE END DATE: 04/30/2031

Group Awards By:

View Award Description

Congenital Syphilis Treatment Trial (CONSISTENT): Phase IV, Open-label, Randomized Controlled Trial of Amoxicillin vs Benzathine Penicillin in Neonates with Possible Congenital Syphilis - Project Summary/Abstract Syphilis is caused by Treponema pallidum (T. pallidum) that can efficiently cross the placenta during all stages of pregnancy and cause fetal infection. In the absence of timely diagnosis and treatment in pregnancy, congenital syphilis (CS) can occur. CS rates have risen sharply in every region of the US over the past decade. Possible congenital syphilis is defined by in-utero exposure to syphilis in an asymptomatic infant with a negative syphilis evaluation (exam, CSF, CBC, and RPR ≤ 4-fold maternal RPR). Recommended treatment for possible CS is single dose benzathine penicillin G (BPG), an effective therapy that has intermittent shortages. The Congenital Syphilis Treatment Trial (CONSISTENT) was designed to test the efficacy of oral amoxicillin therapy (50 mg/kg po BID) compared to standard single dose intramuscular BPG therapy (50,000 u/kg) measured by serologic response within 6 months of treatment. CONSISTENT is a phase IV, open-label, randomized study that will enroll 374 infants (≥35 weeks) at twelve US clinical sites over a two-year enrollment period. Participants will be invited to participate in an optional pharmacokinetic substudy (n=30), and will have pre- and post-treatment oral/nasal swabs collected for T. pallidum PCR testing to carry out the following aims: Aim 1: Compare the treatment efficacy of liquid oral amoxicillin administered BID x 10 days compared to single dose IM BPG (standard of care) among 374 neonates with possible congenital syphilis; Aim 2: Confirm the oral amoxicillin dose of 50 mg/kg/dose BID for the treatment of congenital syphilis using the target plasma drug concentration of 0.42 mg/L as the MIC for T. pallidum; Aim 3: Assess the performance of quantitative PCR testing for T. pallidum on oropharyngeal and nasal swabs in refining the diagnosis of possible congenital syphilis in exposed neonates. Aim 1 will test the hypothesis that amoxicillin efficacy will be non-inferior (within a 10% margin) compared with standard IM BPG for the treatment of possible CS assessed by serologic RPR response within six months. Aim 2 will test the hypothesis that oral amoxicillin 50 mg/kg/dosed BID will be sufficient to maintain drug levels above the MIC threshold required to treat possible congenital syphilis. Aim 3 will test our hypothesis that newly developed quantitative PCR testing of easily collected oropharyngeal and nasal swabs will help refine and improve the diagnosis of syphilis in infants. Our expected outcome is to identify an alternative oral treatment option for infants with possible congenital syphilis. Our long-term goals are to improve options for the treatment and diagnosis of syphilis in infants to reduce long term adverse outcomes.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $2,336,069 )
2026	2026	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH STREET	BIRMINGHAM	AL	35294	JEFFERSON	USA	Allergy and Infectious Diseases Research	000	1	5/12/2026	NEW	$2,336,069
														Subtotal = $2,336,069

Grand Total All Awards = $2,336,069

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Congenital Syphilis Treatment Trial (CONSISTENT): Phase IV, Open-label, Randomized Controlled Trial of Amoxicillin vs Benzathine Penicillin in Neonates with Possible Congenital Syphilis

Award Number: U01AI195199

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/12/2026

PERIOD OF PERFORMANCE END DATE: 04/30/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer